Total labs
30
Total footprint
30,000 sq ft
Set to open in 2026, OMX will offer the much-needed lab space needed to scale growing Deep Tech companies — and it will do so within the supportive, well-connected ecosystem built by Science Creates.
Join our community of scientific entrepreneurs developing technologies that include groundbreaking cancer treatments, enhanced battery technologies and seaweed-based biomaterials.
Located in the heart of Bristol and connected to our Old Market incubator, OMX is designed with the specialised services and features that Deep Tech R&D demands, plus the flexibility that growing ventures need.
With 30,000 sq ft of lab, office and meeting space, OMX offers a range of options depending on the size of your company — from lab-only options to full suites including two labs and a private office.
Membership includes access to our platform of support, providing opportunities to attend workshops and events, connect with other founders, and find a mentor.
Express your interest to secure a space at our newest Bristol incubator.
Travel between locations is measured in walking distance
St Philips Rd & Midland Rd
0.5 miles / 11 min
0.7 miles / 15 min
Folium Science is increasing agricultural productivity by enhancing animal welfare and feed efficiency in livestock farming while reducing environmental impact. Its unique CRISPR-Cas technology platform harnesses natural biological systems to safely modulate animal microbiomes by regulating metabolic functions and targeting unwanted bacteria with extreme precision. This approach helps reduce reliance on antibiotics and can be applied to both plants and soil to improve their bacterial biomes for optimal growing conditions.
Argonaute RNA is developing safe, reliable and targeted methods of temporarily silencing genes in different tissue cells. It does this via the proprietary modification of small interfering RNA (siRNA), using a novel stabilisation method to overcome previous obstacles to developing siRNA drugs for healthcare.
Carbometrics is striving to improve diabetes patient care by enhancing technology for continuous glucose monitoring. The team aims to pave the way for a new class of highly-accurate sensors with its groundbreaking synthetic molecule that is both chemically stable and able to bind to glucose in the blood. This follows on from the work of exited startup Ziylo Ltd, which was Science Creates’ very first resident and acquired by Novo Nordisk in 2018.
Invivo Healthcare is developing solutions to better understand and modulate human microbiomes, promoting long-term wellness and a sustainable future of healthcare. Its supplement therapeutics are plant, nutrient and microorganism-based, designed to lead the way in combating the rise of chronic diseases and a reductionist approach to medicine.
Carbometrics is striving to improve diabetes patient care by enhancing technology for continuous glucose monitoring. The team aims to pave the way for a new class of highly-accurate sensors with its groundbreaking synthetic molecule that is both chemically stable and able to bind to glucose in the blood. This follows on from the work of exited startup Ziylo Ltd, which was Science Creates’ very first resident and acquired by Novo Nordisk in 2018.
Zentraxa is precision engineering biomaterials, pushing the boundaries of biopolymer synthesis to develop sustainable, performance-enhancing ingredients for everyday products. Its proprietary technological platform (Zentide) overcomes the biodesign limits of existing, conventional peptide synthesis by designing, producing and testing complex, novel peptides with one universal process. Zentraxa creates bespoke solutions for a range of industries by combining key features from different naturally-occurring proteins, such as stiffness, adhesion or thermal stability.
Epinal is revolutionising the detection and prevention of narcotic-impaired behaviour for safer roads, flights and workplaces. Utilising AI and novel biotechnology that mimics natural sensory mechanisms, it’s developing a handheld breathalyser that generates rapid results with extreme sensitivity and selectivity.
Hone Bio is revolutionising drug delivery using lipid nanoparticles (LNPs) and exploring their potential across multiple therapeutics, including cell and gene therapies, vaccines and autoimmune diseases. Its NanoPilot platform technology engineers LNPs to target specific cell types with extreme precision to optimise drug effectiveness by minimising off-target effects that tend to accumulate in the liver. This unlocks new possibilities for using LNPs to safely treat diseases in other parts of the body that require maximum target specificity in their drug delivery.
CellVoyant is accelerating the development of novel stem cell-based therapies for chronic diseases. Its technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, enable advanced cell analytics and ultimately unlock the controllable manufacturing of any cell and tissue in the body at scale. Built on foundational research at the University of Bristol, CellVoyant works at the intersection of cell biology, computing, engineering and machine learning to carry out its mission.